Novel Cellular Therapeutic Approaches for the Prevention and Management of Graft-Versus-Host Disease

Published

Journal Article (Review)

© 2018, Springer Nature Switzerland AG. Purpose of Review: Pharmacologic immunosuppression is the mainstay of treatment for GVHD, but there is a crucial need for new therapeutic approaches. Our review focuses on the preclinical and clinical evidence supporting immune regulatory cell infusions, allograft engineering, and suicide-gene-transduced donor T cells to mitigate GVHD. We also review potential challenges to the adoption and use of these therapies. Recent Findings: Mesenchymal stromal cells and regulatory T cells appear effective in preventing and treating GVHD in preliminary studies, although methods of isolating and expanding these cells differ and warrant further investigation. Elimination of naïve or host-reactive donor T cells from allografts can prevent GVHD but may increase infection risk. Donor T cells engineered with human caspase 9 are rapidly eliminated after inducible gene activation, preventing GVHD. Summary: Cellular therapeutics are a promising approach to mitigate GVHD. Clinical trials are underway domestically and internationally to establish the safety and efficacy of these approaches.

Full Text

Duke Authors

Cited Authors

  • Jauhari, S; Chao, N

Published Date

  • December 1, 2018

Published In

Volume / Issue

  • 4 / 4

Start / End Page

  • 318 - 326

Electronic International Standard Serial Number (EISSN)

  • 2198-7866

Digital Object Identifier (DOI)

  • 10.1007/s40778-018-0146-4

Citation Source

  • Scopus